fda glp-1 compounding warning october 2025 and Novo Nordisk Warned of Telehealth Takedown. What's Next? Today, the FDA is announcing

The majority of animal trials have been conducted in India [27, 30, 31, 37, 3941], and the USA [26, 3236]

-

10.1016/j.tifs.2008.04.002

MECHANISM CATEGORIES RESEARCH CONDITIONS SAFETY Side effects Hypoglycemia (binds insulin receptor at higher doses) Theoretical organ enlargement with chronic high-dose Theoretical concerns in active malignancy (IGF-1 axis) Known interactions Insulin / sulfonylureas (hypoglycemia risk) Concurrent rhGH not standard Contraindications Active malignancy (IGF-1 axis growth signaling) Pregnancy/lactation (unstudied) Diabetic retinopathy (theoretical exacerbation) REGULATORY STATUS FDA Not FDA-approved